Rosiglitazone Versus Placebo in Chronic Stable Angina
TerminatedPhase 4NCT00225355
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
We wish to see if the drug rosiglitazone, currently used in the treatment of type 2 diabetes, could be used as a new treatment for angina when compared with placebo in overweight subjects who do not have overt diabetes. The drug will be given for 3 months and the subjects will be have their angina tested, by way of exercise testing, angina quality of life questionnaire and 24-hour ECG monitoring before and after using the drug.
Study details
- Official title
- Insulin Sensitisation as a Novel Mechanism to Lessen Ischaemic Burden in Overweight Non-Diabetic Patients With Chronic Stable Angina: A Pilot Study
- Conditions
- Angina Pectoris
- Metabolic Syndrome X
- Interventions
- Drug: Rosiglitazone
- Sponsor
- University of Glasgow
- Collaborators
- British Heart Foundation; GlaxoSmithKline
- Start date
- 2006-02
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United Kingdom
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Chronic stable angina - to see if this improves * Previous positive exercise tolerance test - to ensure that repeating it yields a result * Disease not suitable for coronary intervention (Coronary artery bypass grafting or angioplasty) - so that best routine care is not withheld * Do not have overt diabetes - work on this is being undertaken elsewhere * Body mass index (BMI) greater than 25 Exclusion Criteria: * Diabetes mellitus - see above * Liver failure (ALT\>70U/l, AST\>80U/l) * Renal failure (creatinine \> 130mmol/l) * Cardiac failure - rosiglitazone is contraindicated in those with NYHA 3 and 4 cardiac failure * Physical disability - if it precludes treadmill testing * Women of child bearing capacity * Breast feeding mothers
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00225355